Objective To create an evidence-based position statement regarding the treatment of
vasomotor symptoms associated with menopause. Design The North American Menopause …

Vasomotor symptoms affect as many as 80% of midlife women, but only about one in four
women receive treatment due to many factors. Menopausal hormone therapy remains the …

Background Treatment decisions about menopause are predicated on a transient duration
of vasomotor symptoms. However, evidence supporting a specific duration is weak …

Hot flashes are one of the most common and distressing symptoms associated with
menopause, occurring in more than 75% of postmenopausal women. They are especially …

Many women experience vasomotor symptoms at or around the time of menopause. Hot
flushes and night sweats are considered primary menopausal symptoms that may also be …

Importance Menopause, due to loss of ovarian follicular activity without another pathological
or physiological cause, typically occurs between the ages of 45 years and 56 years. During …

OBJECTIVE: The decline in concentrations of gonadal hormones during menopause gives
rise to a range of physiologic and psychologic changes that may impact a woman's health …

Vasomotor symptoms are the most common medical complaint of perimenopausal and
postmenopausal women. Frequent vasomotor symptoms can be disabling, affecting a …

Vasomotor symptoms (VMS), or hot flashes and night sweats, are hallmarks of the
menopausal transition (MT) and can significantly affect quality of life. 1–4 Up to 80% of …

Aim To review non-hormonal therapy options for menopausal vasomotor symptoms. The
current EMAS position paper aims to provide to provide guidance for managing peri-and …